The Lancet, 375 (9714), 583593.
First, there is supporting evidence for the safety of GLP-1RAs across the board of cognitive and mental disorders, as we retrieved very few studies 44,159,181,182,193,205 suggesting worse neuropsychiatric outcomes associated with these medications (Tables 16, Fig
However, with a review of their medical history, examination of their current state of health, and search for indications and contraindications, there is a concrete basis to determine what the patients condition is and if they may be helped by this semaglutide treatment
Interestingly, Kyn/tryptophan relation, which appears to represent IDO activity, is also elevated in BD patients [232]
GLP-1 medications are changing how millions of people think about their health, but medication alone is only part of the equation